Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Philip Hoffman   and   Sean Pitroda.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.236
         
        
        
     
 
    
        
        - 
            CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
            
            
                Score: 0.189
             
- 
            A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
            
            
                Score: 0.047